echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > up to date!

    up to date!

    • Last Update: 2021-12-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The top 100 varieties of sales were reshuffled
    .

    01 The ranking of top 100 varieties in sales has changed

    01 The ranking of top 100 varieties in sales has changed

    According to the WeChat public account "Fengyun Yaotan", the ranking of the top 100 products sold in 2020 and the first half of 2021 has changed
    .


    On the whole, the sales scale in 2020 will reach 286 billion yuan, a year-on-year decrease of 10.


    Among the top 20 varieties sold, 4 major varieties have entered the country, namely: insulin aspart injection, budesonide suspension for inhalation, ceftazidime for injection, and iodixanol injection
    .

    Among them, insulin aspart injection achieved sales of 4.
    6 billion yuan, a year-on-year increase of 10%; sales in the first quarter of 2021 were 2.
    58 billion yuan, which is expected to increase by 12% year-on-year in 2021; sales of budesonide suspension for inhalation It was 4.
    04 billion yuan, a year-on-year decrease of 27.
    6%; sales in the first quarter of 2021 were 2.
    56 billion yuan, which is expected to increase by 26.
    4% year-on-year in 2021; 2020 sales of ceftazidime for injection were 3.
    97 billion yuan, a year-on-year decrease of 6.
    5%, and sales in the first half of 2021 The amount is 2.
    07 billion yuan, which is expected to increase by 4.
    4% year-on-year in 2021; the sales of iodixanol injection are 3.
    7 billion yuan, a year-on-year decrease of 9.
    1%; the sales in the first quarter of 2021 are 2.
    02 billion yuan, which is expected to increase year-on-year in 2021 9.
    1%
    .

    Cyberlane checked the data of Meinenet and found that in 2020, the sales of terminal insulin aspart injections in China's public medical institutions exceeded 7 billion yuan, and Novo Nordisk had the largest market share
    .


    There are 4 manufacturers of insulin aspart injection, Novo Nordisk, Ganli Pharmaceutical, Zhuhai United Laboratories, and Zhejiang Hisun Pharmaceutical


    The budesonide suspension for inhalation ranks the first in the terminal inhalation products of public medical institutions in China in 2020, with sales of more than 5 billion yuan, and the market share of the original research drug company AstraZeneca is as high as 94.
    63%
    .

    The sales of ceftazidime for injection in China's public medical institutions in 2020 exceeded 5 billion yuan.
    Hainan Hailing Chemical Pharmaceuticals has the highest market share, reaching 55.
    59%, and the original research drug company GlaxoSmithKline accounted for 3.
    77%
    .


    It is worth noting that many pharmaceutical companies such as Qilu Pharmaceutical, Yangzijiang Pharmaceutical, Zhejiang Jutai Pharmaceutical, Chengdu Better Pharmaceutical, and Hunan Kelun Pharmaceutical have already been reviewed


    In the first quarter of 2021, the sales of iodixanol injection in public hospitals in key cities exceeded 300 million yuan, a year-on-year increase of 70%
    .


    There are 7 manufacturers of iodixanol injection, among which Hengrui has the largest market share, exceeding 50%


    It is worth noting that the sales of edaravone injection, the 86th-ranked product in 2020, decreased by 71.
    1% year-on-year
    .


    Edaravone was once a major neurological drug.


    02 Centralized procurement

    02 Centralized procurement

    It is worth mentioning that, driven by the normalization of the national procurement policy, the prices of medicines have been broken down again and again, and sales have been greatly affected
    .

    For example, in the first round of "4+7" centralized procurement, Xinlitai's clopidogrel bisulfate tablets won the bid
    .


    Judging from the sales data of the sample hospitals in the first three years of the PDB database, after the centralized procurement was officially purchased, the total sales volume of clopidogrel bisulfate tablets in 2019 increased slightly, but the sales amount fell sharply


    In the third batch of national centralized procurement, many companies won bids for Apixaban, including well-known pharmaceutical companies such as CSPC, Yangtze River, and Nanjing Zhengda Tianqing
    .


    PDB database sample hospital sales data shows: After the implementation of the procurement results in the fourth quarter of 2020, the sales volume has increased compared with the third quarter, but the sales amount has dropped sharply, with a decrease of 64%


    Undoubtedly, centralized procurement has a certain driving effect on drug sales
    .

    According to the analysis of Industrial Securities, the current market expectation of centralized drug procurement is continuously sufficient, and its impact is gradually desensitized.
    Looking forward to the future, the selection of generic drug products will be converted to low-margin products after substantial price reductions.
    Contributing a small amount of profit has gradually become the norm
    .

    In this context, although the sales volume of selected drugs in centralized procurement has increased rapidly over a period of time, the total sales cannot be fully guaranteed to achieve growth
    .


    Centralized procurement has become a normal trend, and a batch of drugs has been deeply affected by centralized procurement


    03 How do medical representatives win development

    03 How do medical representatives win development

    The impact of centralized drug procurement for medical representatives cannot be underestimated, and the living space of medical representatives is being challenged
    .

    The sixth batch of National Procurement (Insulin Special) has been reported, and the fifth batch of National Procurement and 30 provinces announced the implementation time.
    Domestic and foreign pharmaceutical companies have reported that they have adjusted and laid off employees in their sales teams
    .
    For example: Hengrui directly proposed "strengthening troops and simplifying administration" in the 2021 Interim Report
    .

    In fact, regardless of whether it is a centralized procurement bid or a bid, pharmaceutical companies will adjust their strategic team and structure in the case of reduced sales and profits
    .
    In the future, more varieties will enter the national procurement, and pharmaceutical companies will continue to adjust their sales teams
    .

    The industry believes that the field of innovative drugs cannot be ignored for the future development of pharmaceuticals
    .
    Taking the domestic market as an example, the country is speeding up the review and approval of tumor-targeted drugs, and Hengrui's monoclonal antibody drugs have been approved for marketing one after another
    .
    According to statistics, by 2035, China's pharmaceutical market will exceed 8 trillion yuan, and innovative drugs will exceed 5.
    7 trillion yuan.
    The innovative drug market will win a broad living space for pharmaceutical representatives
    .

    For this reason, the future development of the pharmaceutical industry is still inseparable from the support of pharmaceutical representatives, but this also requires pharmaceutical representatives to improve their professional capabilities in order to better develop in the market
    .

    Attachment: List of Top 100 Varieties in Sales

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.